 There have been four previous Total Therapy TT1 through IIIB studies for multiple myeloma at the MIRT from 1989 to present. Results have shown that participants treated on these studies had better outcomes meaning they have lived longer and had better responses to treatment when compared to individuals treated with standard chemotherapy. 